Guardant Health: Stock Opportunity Ahead of Earnings and Options Signals

Guardant Health (NYSE: GH) stock has become a focal point for investors ahead of its upcoming earnings release.

Earnings Outlook: Why the Buzz?

Analysts project Guardant Health to post quarterly revenue of $320 million and EPS of $0.58, representing a 15% YoY increase. CEO Dr. Bill ... highlighted the launch of the new cancer screening panel Guardant360 during the earnings call.

Options Market Signals: VIX and Gamma Dynamics

■Implied Volatility (IV) sits at 45%, up 5% week‑over‑week.

■Open Interest rose 30% to 1.2 million contracts.

■Gamma squeeze risk emerges near the $23.50 support level, potentially intensifying downside pressure.

Competitive Edge of the Clinical Portfolio

Guardant’s Guardant360 aims for a 20% market share in the liquid biopsy space, outpacing rivals like Natera and Illumina. Ongoing strategic partnerships further bolster its pipeline.

Institutional Appetite and Portfolio Diversification

■Major funds such as ARK Invest and Fidelity have added fresh long positions.

■45% of investors rate the stock as a “Buy.”

■Short interest stands at 12%, down 3% from the prior quarter.

Markets are watching Guardant Health’s earnings closely, weighing the uptick in option volatility against growing institutional demand. A beat on revenue and EPS could unlock 20‑30% upside, while a miss may trigger a gamma squeeze and short‑term pullback. Managing exposure and monitoring volatility will be key in the coming weeks.